The Organizing Committee proudly presents the workshop program: Program HBVCure Workshop 2016.

 Wednesday 9 November 2016

  Session 1
  Chairs: Fabien Zoulim and Scott Fung

08.45 AMLampertico, Pietro 2013Current Status of HBV Therapy
Pietro Lampertico, MD, PhD
University of Milan, Italy University of Milan, Italy
09.05 AMJanssen, Harry 2013Why do we need new treatments and what is our definition of cure?
Harry Janssen, MD, PhD
Toronto Centre for Liver Disease, Canada
09.25 AMDiscussion
09.45 AMCoffee break & Group Picture
  Session 2
  Chairs: Stephen Locarnini and Charles Boucher
10.30 AMNew Treatment Options: Virological Approach
 - Entry inhibition
Urban, Stephen, 2016 120x160Stephan Urban, PhD
Heidelberg University, Germany
 - CCC – DNA inhibition
Levrero, Massimo 2016 120Massimo Levrero, MD
University La Sapienza, Rome, Italy
 - Small interfering RNA’s
Locarnini, Stephen 2015_120x160Stephen Locarnini, BSc, PhD, MBBS, FRC
Victorian Infectious Diseases Reference Laboratory Melbourne, Australia
 - New Nucleoside Analogue & Capsid inhibition
Zoulim, Fabien 2011_120Fabien Zoulim, MD, PhD
INSERM, Villejuif, France
 - Assembly and Secretion Inhibitors
©Allure West Studios.Tim Block, PhD
Hepatitis B Foundation, Doylestown, USA
  Session 3
  Chairs: Mala Maini and Jordan Feld
01.30 PMHow does HBV interact with the immune system?
Thimme, Robert 2016Robert Thimme, MD
University of Freiburg, Germany
01.55 PMNew Treatment options: Immunomodulatory Agents
 - Therapeutic Vaccines 
Chang, Khyong-Mi 120x160Kyong-Mi Chang, MD
University of Pennsylvania, Philadelphia, USA
 - Adaptive Immunity: - PDL Blockers
Maini, Mala 2016Mala Maini, Prof.
University College London, UK
 - Innate Immunity
Gehring, Adam 2014Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
02.40 PMDiscussion
0300 PMCoffee break
  Session 4
  Chairs: Harry Janssen and Stephan Urban
03.30 PMHow to combine new treatments? Scientific approach
Jordan Feld, MD
Toronto Centre for Liver Disease, Canada
03.50 PMHow to combine new treatments? Clinical approach
Marion Peters, MD
University of California, San Francisco, USA
04.10 PMDiscussion
04.30 PMRoundtable discussion "trial design, treatment endpoints and regulatory approach”.
05.30 PMClosure and adjournment, followed by a workshop dinner